State Street Corp Aligos Therapeutics, Inc. Transaction History

State Street Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.35 - $1.07 $3,395 - $10,379	9,700 Added 9.96%	107,123 $37,000
Q1 2023 May 15, 2023	BUY	$0.87 - $2.11 $31,842 - $77,226	36,600 Added 60.17%	97,423 $84,000
Q2 2022 Aug 15, 2022	SELL	$1.04 - $2.14 $357,690 - $736,016	-343,933 Reduced 84.97%	60,823 $74,000
Q1 2022 May 16, 2022	BUY	$2.08 - $12.2 $30,615 - $179,571	14,719 Added 3.77%	404,756 $870,000
Q4 2021 Feb 14, 2022	BUY	$11.48 - $17.69 $181,441 - $279,590	15,805 Added 4.22%	390,037 $4.63 Million
Q3 2021 Nov 15, 2021	BUY	$14.57 - $17.72 $1.1 Million - $1.34 Million	75,645 Added 25.33%	374,232 $5.8 Million
Q2 2021 Aug 16, 2021	BUY	$20.3 - $33.6 $2.57 Million - $4.25 Million	126,447 Added 73.46%	298,587 $6.09 Million
Q1 2021 May 17, 2021	BUY	$19.1 - $34.94 $233,363 - $426,896	12,218 Added 7.64%	172,140 $3.91 Million
Q4 2020 Feb 16, 2021	BUY	$13.2 - $32.74 $2.11 Million - $5.24 Million	159,922 New	159,922 $4.42 Million

253K

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $751M
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.